Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
NRG/RTOG 0815: 6 mo STAD + dose-escalated RT in IR PCa missed OS (HR 0.87, p=0.13) but cut DM (HR 0.35) and PSA failure (HR 0.60).
ASTRO 2026 centers on biomarker selection for short-term ADT with RT: Decipher Int/High gets 8% absolute 10-yr DM benefit vs 1% Low GC in RTOG 0815, and PAM50 Luminal B predicts STADT benefit with salvage RT in SPPORT (5-y FFP 31% vs 10%). GETUG P05: brachy boost no bPFS gain over 80 Gy EBRT in IR PCa (88.0 vs 88.2%).
read the full digest →Studies · 149
- NRG/RTOG 0815OS HR 0.87 (95% CI 0.72-1.04, p=0.13), not met; 6 mo STAD + dose-escalated RT cut PSA failure (HR 0.60) and DM (HR 0.35) in IR PCa.
- RTOG 0815 Genomic Classifier (Decipher) AnalysisAdding STAD to RT gave an 8% absolute 10-yr DM benefit with Int/High Decipher vs 1% with Low GC, in intermediate-risk prostate cancer.
- LUNAR vs SATURNIPTW-adjusted euPFS HR 1.39 (95% CI 0.56-3.45), p=0.47, SBRT+RLT vs SBRT+6mo AAT in M1 oligorecurrent PCa post-RP; n=63.
- NRG/RTOG 0534 SPPORT PAM50 AnalysisPAM50 Luminal B predicts STADT benefit with salvage RT: 5-y FFP benefit 31% vs 10% non-Luminal B (p-int=.01).
- GETUG P055-yr bPFS 88.0 vs 88.2% (p=0.90): 46 Gy EBRT + LDR/HDR boost no better than 80 Gy EBRT in IR prostate without ADT.
- PROSTOX Ultra (SCIMITAR/EXCALIBUR)Continuous AUC 0.814 (SCIMITAR) and 0.824 (EXCALIBUR) for late G2+ GU toxicity after post-RP prostate bed SBRT; recalibrated 0.25 threshold gives pooled AUC 0.748.
- Biomarkers in the Post-operative Setting for Prostate Cancer (review)Spratt ASTRO 2026 review: PAM50 luminal B predicts apalutamide benefit with salvage RT in NRG GU006 (5y MFS 95% vs 82%, HR 0.27); non-luminal B no benefit.
- GUAM International Consensus Guideline on GU Adverse EventsFirst RT-specific GU AE guideline: 48-expert Delphi, 31 key questions; 76% favor moderate hypofractionation over SBRT at baseline IPSS 15-19.
- REVELUTIONRelugolix vs leuprolide with RT: 12-mo IPSS 5.66 vs 9.22 (p=0.039) and EPIC-CP total 12.25 vs 17.25 (p=0.02), post hoc PRO analysis.
- RTOG 3506 (STEEL)PFS HR 0.62 (80% CI 0.42-0.91, one-sided p=0.052) adding 24mo enzalutamide to SRT + 24mo GnRHa in high-risk BCR post-RP.
- SWOG S1827/MAVERICKMRI surveillance alone beat MRI + PCI for cognitive failure-free survival, HR 0.60 (90% CI 0.46-0.78), in LS- and ES-SCLC without brain mets after first-line therapy.
- PACE-A≥1 urinary pad 14/29 (48%) RP vs 3/36 (8%) SBRT; BCF HR 0.48 (95% CI 0.16-1.46), mFU 8 yrs, GG1-2 localised PCa.